Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Linsitinib + Pictilisib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Linsitinib | OSI-906 | IGF-1R Inhibitor 17 | Linsitinib (OSI-906) is a small molecule dual inhibitor of IGF-1R and IR, which leads to decreased tumor cell proliferation (PMID: 21425998, PMID: 31792037). | |
Pictilisib | GDC-0941|GDC0941|GDC 0941 | PI3K Inhibitor (Pan) 42 | Pictilisib (GDC-0941) inhibits isoforms of PI3K, which inhibits PI3K/AKT signaling resulting in antitumor activity, including inhibition of tumor growth (PMID: 19584227). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA amp | triple-receptor negative breast cancer | sensitive | Linsitinib + Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, Linsitinib (OSI-906) enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766). | 27196766 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|